317P - Effect of body mass index on survival in patients with epithelial ovarian cancer

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Ovarian Cancer
Aetiology, Epidemiology, Screening and Prevention
Presenter Suzy Gohar
Citation Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585
Authors S.F. Gohar1, A. Abdel Ghany1, S.S. Soliman2
  • 1Clinical Oncology, Faculty of Medicine - Menoufia University, 32511 - Shebin El Kom/EG
  • 2Public Health And Community Medicine, Faculty of Medicine - Menoufia University, 32511 - Shebin El Kom/EG

Abstract

Background

Higher body mass index (BMI) is an independent and well-established prognostic factor for mortality for several hormone-related cancers, such as breast and endometrial cancer. As a hormone-dependent cancer, ovarian cancer, however, has been inked inconsistently to obesity. Approximately 12% of patients with ovarian cancer are obese.

Methods

This retrospective study included 66 patients with epithelial ovarian cancer who came to oncology department Menoufia University from January 2011 to April 2014. Patient data were collected, from patients' files including their epidemiological characteristics, disease characteristics, time to progression, overall survival and their fate. BMI was calculated using the formula weight (in kilograms) divided by height (in meters) squared and was graded according to World Health Organization (WHO) system. Results were collected, tabulated and statistically analyzed by an IBM compatible personal computer with SPSS statistical package version 20.

Results

Within the studied group 3 patients (4.5%) were underweight, 11 (16.7%) had normal BMI, 17 (25.8%) were overweight, 13 (19.7%) had moderate obesity, 8 (12.1%) had severe obesity and 14 (21.2%) had very severe obesity. There were no significant associations regarding BMI and disease stage, pathology, initial tumor marker level, platinum sensitivity and overall survival.

Conclusions

In epithelial ovarian cancer patients, high BMI had no significant relation with disease stage, and platinum sensitivity and did not adversely affect time to progression and overall survival.

Clinical trial indentification

Legal entity responsible for the study

Menoufia University

Funding

Menoufia University

Disclosure

All authors have declared no conflicts of interest.